What top creators are saying about SELLAS Life Sciences Group, Inc.(SLS)

The speaker called the stock a short and said it had no value, but provided no supporting details or price target.

Appeared in the performance-screen review without a specific investment thesis.

The speaker directly advised a viewer to exit the position, saying it could materially reduce the account's Sharpe ratio.

The speaker calls SLS a great short, without providing supporting analysis, a price target, or timing guidance.

The speaker explicitly called SLS a great short, without providing reasoning, a price target, or a timeline.

The speaker called the stock an easy short and said shorting it was a Wall Street consensus, while noting he could be wrong about the drugs.

The speaker said he was short the stock and considered it worthless, though no supporting clinical or financial details were provided.

SLS was mentioned without meaningful analysis or an investment view.

The speaker predicted that SLS would fall to about 50 cents, but offered no reasoning or timeframe.

Shkreli said he was short SLS and thought it was worthless, but provided little supporting clinical or financial analysis.

The remarks were strongly bearish, questioning whether its treatment would extend patients’ lives, but were mocking rather than supported by detailed clinical data.

Anticipates a significant downside crash driven by expected failure in upcoming clinical trial endpoints and poor patient outcomes.

High-conviction short opportunity driven by skepticism that its lead AML asset will fail clinical trials, with expectations the stock will head to zero.

Fundamental short opportunity based on anticipated clinical trial failure, though subject to high volatility and short squeeze risk up to $20 leading into data readout.

Considered an unviable biotech with heavily questioned drug science, viewed with high conviction as a short candidate expected to fall toward zero upon trial data release.

Maintaining a short position ahead of the 80th clinical event milestone due to physician feedback indicating a low probability (25% or lower) of clinical success.

Extremely high borrow rate and skepticism over clinical trial data suggest a strong short opportunity.

Viewed as a high-risk 'scam' with potentially manipulated trial data and historical failures in cancer vaccines.

Predicts the Regal clinical trial will fail as improved general survival rates in AML will invalidate the control group comparison.

Extremely bearish view with a strong recommendation to 'sell everything' and 'get the fuck out of it ASAP'. The speaker believes the company's drug 'does not work' and notes a 400% borrow rate, indicating high short interest.

The speaker calls the stock 'a short', but notes it is difficult to time because the data release for its 'biggest binary' event is 'very opaque'.

The speaker expressed a simple bullish sentiment, noting its recent favorable price action: 'SLS has been creeping up. I like it. Let's go.'